1.
Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Oct. 13];2:S57. Available from: https://skin.dermsquared.com/skin/article/view/455